Product category review
GLP-1 Supplements: What’s Actually In Them
Not one of these products contains a GLP-1. What they contain instead is worth knowing — and one of the three ingredients does have evidence behind it.
- −0.88 kgAverage weight change on berberine, pooled across 23 randomised trials
- −14.9%Average body weight change on prescription semaglutide at 68 weeks
- 2 minHow long your own GLP-1 survives before an enzyme destroys it
- 1FDA warning letters over supplement GLP-1 claims, against 100+ aimed at drug sellers
The short version
A product sold as a “GLP-1 supplement” does not contain GLP-1, and does not contain semaglutide or tirzepatide. It could not legally do so — those are prescription drugs, and a supplement containing one would be an unapproved drug rather than a supplement. The cheaper thing that does contain the drug is compounded semaglutide, which raises different questions entirely.
What the name means is that the product claims to help your body release more of its own GLP-1. That is a real hormone and it can genuinely be nudged by what you eat. The problem is not that the idea is nonsense. The problem is that the effect it produces and the effect the drugs produce are separated by a factor of roughly five thousand, for a reason that has nothing to do with product quality.
Why boosting your own GLP-1 is not the same thing
Your gut releases GLP-1 after you eat. Within about two minutes, an enzyme called DPP-4 has broken most of it down. That is not a flaw — it is how the hormone is designed to work, as a brief signal tied to a meal.
Semaglutide is a structurally modified version of that hormone, rebuilt specifically so DPP-4 cannot dismantle it. That is the entire pharmaceutical achievement. Its half-life is roughly a week rather than roughly two minutes — about five thousand times longer — which is why a single weekly injection produces continuous appetite suppression instead of a signal that is gone before you have finished eating.
Worth knowing
A supplement that genuinely increased your own GLP-1 would still produce a signal lasting minutes. The drug’s advantage is not that it raises GLP-1 higher. It is that it does not go away.
This is the same shape of problem we found with GLP-1 patches, where the obstacle was molecular size rather than duration. In both cases the marketing borrows the vocabulary of a drug whose defining property the product does not have.
What is actually in the bottle
Formulations vary, but three ingredients account for most of this category. They are not equally supported, and lumping them together is how a weak product borrows credibility from a reasonable one.
-
Limited evidence
Berberine
The ingredient marketed as “nature’s Ozempic”, a plant alkaloid. It is the most-studied item in this category and the effect is real but small: pooling 23 randomised controlled trials gives an average weight change of −0.88 kg, with an earlier 12-study analysis finding −2.07 kg. Much of the underlying research was conducted in China in people with metabolic disease, so how well it generalises is unclear. There is no good human evidence that it raises GLP-1 at all — its effects appear to run through other metabolic pathways, which makes the “nature’s Ozempic” framing wrong even on its own terms.
-
Best supported
Soluble fibre
Psyllium husk, inulin, glucomannan. This is the one ingredient in the category with a defensible mechanism: soluble fibre absorbs water, slows how quickly nutrients reach the small intestine, and does stimulate the cells that release GLP-1. It is a genuine effect on satiety, and it is also the cheapest thing on this list. What it is not is a substitute for a drug — the GLP-1 it triggers is your own, and it is gone in minutes.
-
Weakest case
Chromium
Usually chromium picolinate. There is some evidence it modestly improves glycaemic measures in people with diabetes. Its relevance to weight loss in people without diabetes is thin, and its relevance to GLP-1 specifically is close to absent. It appears in these formulations largely because it is inexpensive and has a metabolic-sounding reputation.
We do not publish doses for these ingredients. None has approved labeling or an established human dose for weight loss, and the figures in circulation come from product marketing rather than from trials.
The numbers side by side
| Berberine | Semaglutide | Tirzepatide | |
|---|---|---|---|
| Average weight change | −0.88 kg | −14.9% | −20.9% |
| Trial length | Varies, mostly 8–24 weeks | 68 weeks | 72 weeks |
| Evidence base | 23 pooled trials, mostly small | Phase 3 (STEP 1) | Phase 3 (SURMOUNT-1) |
| Raises GLP-1 in humans? | Not demonstrated | Not applicable — it is a GLP-1 | Not applicable |
| Signal duration | n/a | About a week | About a week |
| Prescription required | No | Yes | Yes |
These are not head-to-head comparisons and the units differ — the berberine figure is an absolute weight change pooled across trials, the drug figures are percentage change in single trials. That mismatch is itself informative: the supplement literature reports in kilograms because the percentages would be unflattering. All three drug trials included lifestyle intervention.
Why nobody is stopping them
Dietary supplements do not need FDA approval before going on sale. The manufacturer is responsible for its own safety and labeling claims, and the agency generally acts only after a product is already on the market. A supplement may not claim to treat a disease, but it may make “structure/function” claims — supports healthy metabolism, promotes satiety — and that is a wide door.
The contrast with the drug side is stark. Across 2025 and 2026 the FDA issued more than a hundred warning letters to compounders and telehealth companies over GLP-1 marketing. Over the same period, trade reporting has identified a single supplement-specific warning letter touching GLP-1 claims — issued in December 2024, and prompted less by the GLP-1 framing than by the company claiming FDA approval it did not have.
Worth knowing
Enforcement has concentrated almost entirely on products that contain a GLP-1. Products that merely invoke one have gone largely unchallenged — which is the reason this category exists at the scale it does.
Frequently asked questions
-
Is there an over-the-counter version of Ozempic?
No. Semaglutide is a prescription drug in every country that has approved it. A product sold without a prescription either does not contain it, or is being sold illegally.
-
Does berberine actually work for weight loss?
It produces a small, measurable effect. Pooled across 23 randomised trials the average is under a kilogram. Whether that is worth the cost is a reasonable question to ask; whether it is comparable to a prescription GLP-1 is not a close call.
-
Can food raise GLP-1 naturally?
Yes, and it does so every time you eat. Protein and soluble fibre produce a larger response than refined carbohydrate. This is real physiology and worth acting on — it is simply not a mechanism that scales up into drug-sized weight loss, because the hormone is cleared within minutes regardless of how much of it you release.
-
Are these supplements dangerous?
The main documented risk is not toxicity but interaction — berberine in particular affects the liver enzymes that metabolise many common prescriptions. Because supplements are not pre-approved, contents can also differ from the label. Anyone taking prescription medication should raise it with a pharmacist before adding one.
Sources and method
- Berberine, pooled result. The effect of berberine on obesity indices: a systematic review and meta-analysis, International Journal of Obesity, 2025. 23 randomised controlled trials; mean difference in body weight −0.88 kg.
- Berberine, earlier analysis. Dose-response meta-analysis of randomized controlled trials, 2020. 12 studies; mean difference −2.07 kg. We cite both rather than the more flattering one.
- Semaglutide trial result. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021. Mean change −14.9% at 68 weeks.
- Tirzepatide trial result. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022. Mean change −20.9% at 72 weeks on the highest dose arm.
- FDA position on unapproved GLP-1 products. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.
- What we could not verify. The count of supplement-specific FDA warning letters comes from trade reporting, not from an exhaustive search of the FDA warning letter database, which is not reliably filterable by claim type. We have stated it as reported and would correct it if a fuller count exists. The half-life figures are drawn from approved labeling and standard pharmacology; the “roughly five thousand times” comparison is our own arithmetic from those two numbers.
Do GLP-1 patches work? → What licensed providers charge → How we source and verify →
Published 26 August 2026. We recheck the evidence base on this page twice a year.